Aditxt, Inc. announced the formation of a U.S. based wholly- owned subsidiary, Pearsanta, Inc., to accelerate the growth of Aditxt's second program, AditxtScore™, through future strategic revenue and growth-oriented transactions. Anthony Voorhies, currently the head of the AditxtScore™ division, will serve as President of Pearsanta. Mr. Voorhies has over 20 years of clinical diagnostics and healthtech industry experience.

He previously held executive roles with multiple private and public healthcare companies and has commercialized a broad range of diagnostic tools, biomarkers, and FDA-cleared medical devices for early stage and established profitable companies. Under Mr. Voorhies' leadership, the AditxtScore™ division has successfully grown from inception to commercialization and into revenues in just under two years. Pearsanta will be headquartered at AditxtScore's™ existing immune monitoring center, a 25,000-square-foot CLIA-certified, CAP-accredited facility in Richmond's downtown biotech park which employs a robust and talented team of scientists and laboratory personnel.

Pearsanta will focus on the continued commercialization of AditxtScore™, a proprietary platform designed to provide a personalized profile of the immune system which the Company believes is key to unlocking the potential of precision medicine.